Dr. Tagliaferri has over three decades of experience overseeing clinical development, drug safety, regulatory strategy and developing value-creation pathways for clinical-stage and commercial-stage assets. She has served on our Board of Directors since November 2025. At Nektar Therapeutics, Dr. Tagliaferri, is responsible for leading clinical development and medical strategy for a broad portfolio of oncology and immunology programs, and for establishing key strategic partnerships. Dr. Tagliaferri currently serves on the board of directors of Iambic Therapeutics. Prior to Nektar, she served as Chief Medical Officer for KangLaiTe-USA, a privately-held biotechnology company in the oncology space. Dr. Tagliaferri was also a Co-Founder, President and Chief Medical Officer of BioNovo, where she led clinical drug development strategy and operations as well as global regulatory affairs. Dr. Tagliaferri earned her M.D. from the University of California, San Francisco (UCSF) and a B.S. degree from Cornell University.
